C.Uyemura & Co.,Ltd.
C.Uyemura & Co.,Ltd. (CUYRF) Financial Performance & Income Statement Overview
Analyze C.Uyemura & Co.,Ltd. (CUYRF) financial statements (income, balance sheet, and cash flow) across both yearly and quarterly periods.
C.Uyemura & Co.,Ltd. (CUYRF) Income Statement & Financial Overview
Analyze C.Uyemura & Co.,Ltd.’s CUYRF earnings with segmented quarterly and yearly financial statement figures.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $20.52B | $22.56B | $20.78B | $19.98B |
| Cost of Revenue | $12.78B | $13.72B | $12.63B | $12.12B |
| Gross Profit | $7.74B | $8.84B | $8.15B | $7.87B |
| Gross Profit Ratio | $0.38 | $0.39 | $0.39 | $0.39 |
| R&D Expenses | $0.00 | $0.00 | $0.00 | $0.00 |
| SG&A Expenses | $3.20B | $3.44B | $3.53B | $3.36B |
| Operating Expenses | $3.20B | $3.44B | $3.53B | $3.36B |
| Total Costs & Expenses | $15.98B | $17.17B | $16.16B | $15.47B |
| Interest Income | $161.25M | $116.16M | $117.66M | $99.96M |
| Interest Expense | $6.61M | $0.00 | $0.00 | $3.49M |
| Depreciation & Amortization | $636.86M | $551.65M | $537.00M | $535.77M |
| EBITDA | $5.55B | $6.15B | $5.14B | $5.79B |
| EBITDA Ratio | $0.27 | $0.27 | $0.25 | $0.29 |
| Operating Income | $4.54B | $5.39B | $4.62B | $4.51B |
| Operating Income Ratio | $0.22 | $0.24 | $0.22 | $0.23 |
| Other Income/Expenses (Net) | $135.32M | $195.00M | -$25.00M | $742.50M |
| Income Before Tax | $4.67B | $5.59B | $4.60B | $5.25B |
| Income Before Tax Ratio | $0.23 | $0.25 | $0.22 | $0.26 |
| Income Tax Expense | $1.52B | $1.39B | $1.62B | $1.50B |
| Net Income | $3.16B | $4.20B | $2.97B | $3.75B |
| Net Income Ratio | $0.15 | $0.19 | $0.14 | $0.19 |
| EPS | $195.77 | $260.25 | $184.33 | $232.51 |
| Diluted EPS | $195.77 | $260.25 | $184.33 | $232.51 |
| Weighted Avg Shares Outstanding | $16.13M | $16.13M | $16.13M | $16.12M |
| Weighted Avg Shares Outstanding (Diluted) | $16.13M | $16.13M | $16.13M | $16.12M |
Over the past four quarters, C.Uyemura & Co.,Ltd. demonstrated steady revenue growth, increasing from $19.98B in Q1 2024 to $20.52B in Q4 2024. Operating income reached $4.54B in Q4 2024, maintaining a consistent 22% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at $5.55B, reflecting operational efficiency. Net income dropped to $3.16B, with EPS at $195.77. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan